MaxCyte (NASDAQ:MXCT) Upgraded to Hold at Wall Street Zen

MaxCyte (NASDAQ:MXCT) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Sunday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, MaxCyte has an average rating of “Hold” and an average price target of $6.00.

MaxCyte Stock Down 1.8%

Shares of MXCT opened at $0.82 on Friday. MaxCyte has a twelve month low of $0.64 and a twelve month high of $3.33. The company has a market cap of $87.45 million, a price-to-earnings ratio of -1.86 and a beta of 1.22. The company has a 50 day moving average of $0.97 and a two-hundred day moving average of $1.36.

Institutional Investors Weigh In On MaxCyte

A number of institutional investors have recently modified their holdings of MXCT. Mirabella Financial Services LLP increased its stake in shares of MaxCyte by 24.2% in the 3rd quarter. Mirabella Financial Services LLP now owns 8,200,000 shares of the company’s stock valued at $12,956,000 after purchasing an additional 1,600,000 shares in the last quarter. State Street Corp boosted its holdings in MaxCyte by 4.0% in the 4th quarter. State Street Corp now owns 2,358,384 shares of the company’s stock worth $3,655,000 after buying an additional 91,534 shares during the last quarter. AXA S.A. increased its stake in MaxCyte by 123.2% during the 2nd quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock worth $4,801,000 after buying an additional 1,215,481 shares in the last quarter. Kennedy Capital Management LLC purchased a new stake in MaxCyte during the 3rd quarter worth approximately $3,330,000. Finally, Millennium Management LLC raised its holdings in shares of MaxCyte by 1,082.6% during the fourth quarter. Millennium Management LLC now owns 1,292,773 shares of the company’s stock valued at $2,004,000 after acquiring an additional 1,183,461 shares during the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.